External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology APVRS 2022
Roche and Genentech at

APVRS 2022

November 18 - November 20
Taipei, Taiwan
apvrs.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
03:54 AM
Duration 7mins Meeting Room 701E
Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Lai T, Haskova Z, Mohan S, Silverman D, Tang Y, Lin H
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:27 AM
Duration 7mins Meeting Room 701E
Design and Rationale of the SALWEEN Trial: A Phase 3b/4 Study of Faricimab, a Dual Angiopoietin-2 and Vascular Endothelial Growth Factor-A Inhibitor, in Patients With Polypoidal Choroidal Vasculopathy
Lee WK, Lai T, Iida T, Chen S, Margaron P, Cheung G
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:34 AM
Duration 7mins Meeting Room 701E
End-of-Study Retinal Fluid and Vision Outcomes in the 96-week Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Lai T, Rachitskaya A, Blotner S, Heinrich D, Gune S
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:41 AM
Duration 7mins Meeting Room 701E
Portal Extension Trial of the Port Delivery System With Ranibizumab (PDS): Three-Year Follow-Up From the Phase 3 Archway Trial
Chen S, Regillo C, Cavichini Cordeiro M, Blotner S, Jaycock P, Gune S
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:09 AM
Duration 7mins Meeting Room 701E
Central Subfield Thickness Fluctuations and Their Impact on Vision Outcomes Over 96 Weeks in the Archway Trial of the Port Delivery System With Ranibizumab (PDS)
Hwang Y, Chakravarthy U , Blotner S, Heinrich D, Gune S, Sheth V
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:52 AM
Duration 7mins Meeting Room 701E
Faricimab in Neovascular Age-Related Macular Degeneration: Year 1 Results With Week 12 Fluid Data From the Phase 3 TENAYA and LUCERNE Trials
Guymer R, Cheung G, Souverain A, Yang M, Kotecha A, Margaron P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:59 AM
Duration 7mins Meeting Room 701E
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE/RHINE Trials of Faricimab in Diabetic Macular Edema
Chen S, Jaffe GJ, Gerendas BS, Camino A, Tang Y, Haskova Z
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:06 AM
Duration 7mins Meeting Room 701E
Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Cheung G, Holz F, Khanani AM, Kotecha A, Patel V, Willis J
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:13 AM
Duration 7mins Meeting Room 701E
Intraocular Suppression of VEGF-A and Ang-2 Following Intravitreal Administration of Faricimab
Diack C*, Avery R, Stoilov I, Bogman K
Ophthalmology | Neovascular Age Related Macular Degeneration - Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 7mins Meeting Room 701E
Angiopoietin-2 Signalling and Vascular Stability With Faricimab in Diabetic Macular Edema
Liu PK, Haskova Z, Joussen A, Willis JR, Westenskow PD
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:20 AM
Duration 7mins Meeting Room 701E
Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): Year 2 Patient Case Profiles From the Phase 3 TENAYA/LUCERNE Trials
Koh A, Figueroa M, Pearce I, Swaminathan B, Patel V, Kotecha A
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:27 AM
Duration 7mins Meeting Room 701E
Supplemental Intravitreal Ranibizumab Injections in Patients with the Port Delivery System With Ranibizumab (PDS) in the Phase 3 Archway Trial for Neovascular Age-Related Macular Degeneration (nAMD)
Chang A, Pieramici D, Gune S, DeGraaf S, Barteselli G, Heinrich D
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 7mins Meeting Room 701G
Key Surgical Pearls for Best Practice During the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure
Okada M, Wieland M, Jaycock P, Menezes A, Singh N, Malhotra V
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.